Pharmaceutical
Health
Therapy

Corcept Therapeutics

$11.27
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.26 (2.36%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell CORT and other stocks, options, ETFs, and crypto commission-free!

About

Corcept Therapeutics Incorporated Common Stock, also called Corcept Therapeutics, is a commercial-stage pharmaceutical company, which engages in the discovery, development and commercialization of medications to treat severe metabolic, oncologic and psychiatric disorders. It focuses on the development of drugs for disorders that are associated with a steroid hormone called cortisol. Read More Its products include korlym and korlym support. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Menlo Park, CA.

Employees
166
Headquarters
Menlo Park, California
Founded
1998
Market Cap
1.27B
Price-Earnings Ratio
18.91
Dividend Yield
0.00
Average Volume
1.36M
High Today
$11.59
Low Today
$11.01
Open Price
$11.04
Volume
382.93K
52 Week High
$20.00
52 Week Low
$9.14

Collections

Pharmaceutical
Health
Therapy
Technology

News

Yahoo Finance33m

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Incorporated - CORT

NEW YORK, NY / ACCESSWIRE / March 26, 2019 / Pomerantz LLP is investigating claims on behalf of investors of Corcept Therapeutics Incorporated (''Corcept'' or the ''Company'') (CORT). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.

5
Yahoo Finance5h

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing in Corcept Therapeutics Incorporated to Contact the Firm

NEW YORK--(BUSINESS WIRE)-- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Corcept Therapeutics Incorporated ("Corcept" or the "Company")(CORT) of the May 13, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you invested in Corcept stock or options between August 2, 2017 and February 5, 2019 and would like to discuss your legal rights, click here: www.faruqilaw.com/CORT. There is no cost or...

2
Yahoo Finance6h

Hagens Berman Reminds Corcept Therapeutics (NASDAQ: CORT) Investors of May 13, 2019 Lead Plaintiff Deadline

SAN FRANCISCO, March 26, 2019 (GLOBE NEWSWIRE) -- Hagens Berman Sobol Shapiro LLP reminds investors in Corcept Therapeutics Incorporated (CORT) of the May 13, 2019 Lead Plaintiff deadline in the pending securities class action.

4

Earnings

$0.07
$0.13
$0.18
$0.24
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 7, After Hours

Popular Stocks

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.